Giuliana Grossi

Short and long nighttime sleep duration, along with daytime napping, were associated with a moderate increase in risk of cardiovascular diseases.

Evidence has suggested a relationship between screen time and poor sleep among youth, however, little evidence has been provided for adults.

Mother's who follow the DASH dietary pattern experience better sleep health for themselves and their infants, according to new study.

When compared to traditional in-lab polysomnography, the Circul ring-worn oximeter produced similarly reliable results in detecting obstructive sleep apnea (OSA).

New data, alongside any future research operating from a family systems approach can provide novel insight into sleep, mental health, and attachments.

Patients with pulmonary tuberculosis (TB) exhibited an improvement in quality of life and a reduction in treatment costs by utilizing a digital medication event reminder monitor (MERM).

Dr. Sara Mednick's pursuit to understand how to improve intelligence led her to an extensive career of studying the various mechanisms of sleep.

The effect of sleep health on disease prevention may have a profound impact on women when it comes to systemic lupus erythematosus (SLE).

For the second annual Interstitial Lung Disease Day, Dr. Briana DiSilvio expands on the background of ILDs and the latest care practices.

Dr. Mednick's latest book, The Power of the Downstate, focuses on the integrated role of sleep by following the "rhythm of upstates and downstates" that people operate in every day.

Cases and hospitalizations due to EV-D68, a rare form of enterovirus associated with acute flaccid myelitis (AFM), have been increasing among children across the country.

Nonpharmacological sleep interventions that focused on earlier sleep schedules can serve as a “simple, pragmatic, effective way to meaningfully increase sleep duration that could have important benefits for child health.”

Acadia Pharmaceuticals announced that the FDA granted a priority review for trofinetide and set March 12, 2023 as the PDUFA date.

The FDA accepted the Biologics License Application (BLA) and granted priority review for velmanase alfa, an investigational enzyme replacement therapy intended to treat the ultra rare disease.

DaxibotulinumtoxinA-lanm (Daxxify) is the first and only neuromodulator stabilized with Peptide Exchange Technology (PXT) and addresses the treatment duration effect.

Respiratory symptoms are significant among individuals with a history of smoking tobacco even without airflow obstruction.

Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at ERS 2022 regarding the InPedILD clinical trial.

Late-breaking data presented at ERS Congress 2022 show that inhaler sensors and mobile health (mHealth) applications combined with pharmacist counseling improved treatment adherence for patients with uncontrolled asthma.

According to recent research, there’s no association between insomnia and vitamin D deficiency, although, insomnia did correlate with abnormal anxiety and depression scores among university students.

These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.

CDC investigators stated that the expansion of telehealth strategies is “urgently needed” to provide medications for opioid use disorder because it could increase retention in care and improve outcomes for OUD.

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.

Recent research from the National Psoriasis Foundation (NPF) found that 1 in 3 individuals living with psoriatic conditions experience depression.

In the second portion of the Rare Disease Report: CDKL5 podcast, Elia Pestana Knight, MD, a pediatric epileptologist shares her clinical expertise on CDKL5 deficiency disorder (CDD).

A novel biomarker was identified for posterior uveitis that postulates previously undetected sources of green and red emission fluorescent components (GEFC/REFC).

According to new research, stroke occurrence trends coinciding with tuberculous meningitis (TBM) are suggested to have regional characteristics.

Olipudase alfa (Xenpozyme) was developed by Sanofi to treat symptoms unrelated to the central nervous system in pediatric and adult patients with the life-threatening condition.

The FDA granted priority review for the Bioloigics License Application (BLA) Sanofi submitted for efanesoctocog alfa indicated for individuals with hemophilia A with a decision date set for February 28, 2023.

In the first episode of a 2-part Rare Disease Report, Whitney Mitchell, mother and caregiver to her 5 year old daughter Havilah, shared her experience leading up to, and now living with, Havilah’s CDKL5 deficiency disorder diagnosis.

Pemigatinib (Pemazyre) becomes the first and only targeted treatment for adults with extremely rare and aggressive blood cancer.